EUREKING: management transactions · France · AMF

About EUREKING

eureKING is a French listed company that was launched as a Special Purpose Acquisition Company (SPAC) with a healthcare-focused investment thesis centered on biomanufacturing in Europe. The company was admitted to trading on Euronext Paris in May 2022 under ISIN FR0014009ON9 and ticker KINGS, and raised approximately €150 million to finance a targeted business combination in the biopharmaceutical manufacturing ecosystem. Its creation was backed by eureKARE, a French specialist in building and financing biotechnology companies, with the strategic ambition of creating a European reference platform in biologics manufacturing. eureKING was not designed as a traditional operating pharmaceutical company. Instead, it was structured as an acquisition vehicle intended to source, negotiate and combine with a target company holding industrial, technological or service capabilities related to biomanufacturing. Its initial scope included businesses involved in the production of biological substances, innovative drug manufacturing, and adjacent industrial healthcare services. Public communications emphasized the company’s intention to support the development of new treatments for serious diseases by helping scale biotherapies and biopharmaceutical innovation. During its short listed life, eureKING explored several strategic transactions in the sector, including combination discussions with Skyepharma and SCTbio in 2023. These negotiations reflected the company’s original role as a consolidation platform aimed at assembling an industrial footprint in European healthcare manufacturing. However, the trajectory later changed materially: in late November 2023, shareholders approved an early dissolution and liquidation process, which led to the company’s delisting. This is the key turning point in eureKING’s corporate history and should be considered essential context when assessing the name. Geographically, the company was conceived as a pan-European vehicle with a French base and an investment focus on European industrial assets. Its investor profile naturally appealed to market participants looking for exposure to life sciences, advanced healthcare manufacturing and listed SPAC structures. Notable facts include its status as the first European healthcare SPAC dedicated to bioproduction, its significant initial fundraising, its association with a specialist biotech sponsor, and its eventual liquidation rather than execution of a long-term operating strategy. In short, eureKING is best understood as a short-lived but distinctive listed investment vehicle in the European health manufacturing space, rather than a conventional operating pharma group.